Analyzing Apricus Biosciences (APRI) and Sanofi (SNY)
Apricus Biosciences (NASDAQ: APRI) and Sanofi (NYSE:SNY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.
This table compares Apricus Biosciences and Sanofi’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
15.3% of Apricus Biosciences shares are owned by institutional investors. Comparatively, 9.3% of Sanofi shares are owned by institutional investors. 3.6% of Apricus Biosciences shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Sanofi pays an annual dividend of $1.10 per share and has a dividend yield of 2.2%. Apricus Biosciences does not pay a dividend. Sanofi pays out 28.1% of its earnings in the form of a dividend.
Earnings and Valuation
This table compares Apricus Biosciences and Sanofi’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Apricus Biosciences||$5.76 million||4.55||-$10.05 million||$0.68||3.01|
|Sanofi||$43.62 billion||2.88||$13.09 billion||$3.92||12.76|
Sanofi has higher revenue and earnings than Apricus Biosciences. Apricus Biosciences is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations and price targets for Apricus Biosciences and Sanofi, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Apricus Biosciences currently has a consensus price target of $4.50, suggesting a potential upside of 119.51%. Sanofi has a consensus price target of $53.50, suggesting a potential upside of 6.94%. Given Apricus Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Apricus Biosciences is more favorable than Sanofi.
Volatility & Risk
Apricus Biosciences has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
Sanofi beats Apricus Biosciences on 9 of the 15 factors compared between the two stocks.
About Apricus Biosciences
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company’s vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company’s vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.